Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 plus Venetoclax in Unfit AML
NCT04038437Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Maximum Tolerated Dose up to 36 months and Adverse Events and Dose Limiting Toxicities up to 36 months. Started Oct 2019; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04038437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038437.